AGP Executive Report
Last update: 9 hours agoGLP-1 Shift to Oral Options: The oral GLP-1 market is projected to surge as Novo and others push easier-to-take formulations, with industry focus expanding beyond weight loss into broader chronic disease benefits. Drug Delivery Innovation: Lexaria’s DehydraTECH is being evaluated to improve oral absorption and reduce side effects, while a separate patent filing targets a new biologics platform built for scalable manufacturing. Clinical Trials & Data: Oku Digital Health launched an ocular-data network to speed trial recruitment and generate real-world evidence, and coverage highlights how connecting real-world data to the patient journey still runs into interoperability and workflow barriers. FDA/Trials Oversight: The FDA is seeking public input on early-phase ibogaine trial design, while ACT Briefs flag gaps in outsourcing oversight as mixed models spread. Cancer Care Updates: Ernexa Therapeutics’ ERNA-101 was selected for a Nature/MD Anderson flash talk, and Regeneron shared new ESMO 2026 research spanning multiple cancers and cancer-associated thrombosis. Pricing Transparency Rules: CMS announced new regulations to make healthcare pricing and coverage info easier to find, compare, and report. Policy & Access: Utah launched AI pilots for healthcare processes, and India’s eSanjeevani hit 50 crore teleconsultations, with women driving over half of visits.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Winners of the 2026 CPHI Pharma Awards Announced]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29162130-947764016-44d3c8749dd37422ac8edc6794bc41af2660ad1b-1890x1063-200x112.png)
